A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Inclusion Criteria:
Exclusion Criteria:
Troy, Michigan 48098, United States
North Richland Hills, Texas 76180, United States
Rosario, 2000, Argentina
Chongqing, 400010, China
Luoyang Shi, 471003, China
Pardubice V, 530 02, Czechia
Dresden, 01277, Germany
Kamakura-shi, 247-0056, Japan
Yamato-shi, 242-0004, Japan